We are live on ! Find out more
OBIO icon

Orchestra BioMed
OBIO

46 hedge funds and large institutions have $130M invested in Orchestra BioMed in 2021 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 4

0% more funds holding

Funds holding: 46 → 46 (0)

0% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 7

1.93% less ownership

Funds ownership: 58.76% → 56.84% (-1.9%)

15% less capital invested

Capital invested by funds: $154M → $130M (-$23.7M)

Holders
46
Holders Change
–
Holders Change %
0%
% of All Funds
0.81%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
7
Increased
7
Reduced
4
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Amitell Capital
Singapore
+$2.45M
2
IC
Ikarian Capital
Texas
+$2.44M
3
DKCM
Davidson Kempner Capital Management
New York
+$2.4M
4
AC
Athanor Capital
New York
+$726K
5
AAA
Affinity Asset Advisors
New York
+$304K

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$2.57M
2
AIC
AWM Investment Company
New York
-$2.56M
3
GL
Governors Lane
New York
-$1.68M
4
KPF
K2 Principal Fund
Ontario, Canada
-$1.64M
5
PC
Periscope Capital
Ontario, Canada
-$1.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
Janus Henderson Group
26
Janus Henderson Group
United Kingdom
$815K -$1.19M -97,471 -57%
KPF
27
K2 Principal Fund
Ontario, Canada
$726K -$1.64M -134,584 -67%
AC
28
Athanor Capital
New York
$669K +$726K +59,579 New
SCM
29
Shaolin Capital Management
Florida
$560K – – –
SCM
30
Suvretta Capital Management
New York
$560K – – –
GPCM
31
Granite Point Capital Management
Massachusetts
$539K – – –
TD Asset Management
32
TD Asset Management
Ontario, Canada
$520K – – –
BCP
33
Berylson Capital Partners
Massachusetts
$519K – – –
MF
34
Magnetar Financial
Illinois
$361K +$4.87K +400 +1%
Millennium Management
35
Millennium Management
New York
$314K – – –
Alyeska Investment Group
36
Alyeska Investment Group
Illinois
$280K – – –
Nomura Holdings
37
Nomura Holdings
Japan
$276K +$304K +25,000 New
6CM
38
683 Capital Management
New York
$112K – – –
ACM
39
Altium Capital Management
New York
$112K – – –
RCM
40
Rivernorth Capital Management
Florida
$112K – – –
WRBC
41
W.R. Berkley Corp
Connecticut
$111K – – –
FIA
42
FNY Investment Advisers
New York
$33K +$36.5K +3,000 New
HI
43
Harbour Investments
Wisconsin
$22K +$24.4K +2,000 New
UBS Group
44
UBS Group
Switzerland
$10K +$10.4K +851 +3,152%
Morgan Stanley
45
Morgan Stanley
New York
$7K +$8K +657 New
TRCT
46
Tower Research Capital (TRC)
New York
$6K +$6.64K +545 New
AIC
47
AWM Investment Company
New York
– -$2.56M -200,000 Closed
GL
48
Governors Lane
New York
– -$1.68M -131,250 Closed
PC
49
Periscope Capital
Ontario, Canada
– -$1.4M -109,461 Closed
MIM
50
Monashee Investment Management
Massachusetts
– -$1.28M -100,000 Closed
1
2
3

OBIO Hedge Fund Activity: Q1 2021 in Review

46 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q1 2021, worth a combined $130M — down 15% from $154M a quarter earlier.

Fund positioning in OBIO was balanced in Q1 2021: 7 funds opened new positions, 7 closed out, 7 added to existing stakes and 4 trimmed.

The largest buyer was Amitell Capital, adding an estimated $2.45M. The largest seller was Wellington Management Group, cutting an estimated $2.57M.

  • 46 institutional investors held Orchestra BioMed (OBIO) as of Q1 2021, unchanged from Q4 2020.
  • Funds reported $130M of Orchestra BioMed stock for Q1 2021, down 15% quarter-over-quarter.
  • 7 funds opened new Orchestra BioMed positions in Q1 2021 and 7 closed out, a net change of 0 holders.
  • The largest Orchestra BioMed buyer in Q1 2021 was Amitell Capital, an estimated $2.45M added.
  • The largest Orchestra BioMed seller in Q1 2021 was Wellington Management Group, an estimated $2.57M sold.

Based on aggregated 13F filings for Q1 2021.